A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
Recruiting
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Gender:
All
Ages:
Between 12 years and 100 years
Trial Updated:
11/29/2023
Locations: Health Concepts, Rapid City, South Dakota
Conditions: Atopic Dermatitis
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
Recruiting
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study compares upadacitinib to dupilumab in adolescent and adult participants with moderate to severe AD who have inadequate response to systemic therapies. Adverse events and change in the disease activity will be assessed. Upadacitinib and dup... Read More
Gender:
All
Ages:
Between 12 years and 64 years
Trial Updated:
11/28/2023
Locations: Health Concepts /ID# 250988, Rapid City, South Dakota
Conditions: Atopic Dermatitis
A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)
Recruiting
The coprimary objectives of the study are to: evaluate the efficacy of rocatinlimab in combination with topical corticosteroid and/or topical calcineurin inhibitor (TCS/TCI), compared with placebo in combination with TCS/TCI at Week 24, assessed using Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD™). evaluate the efficacy of rocatinlimab, in combination with TCS/TCI, compared with placebo in combination with TCS/TCI at Week 24, assessed using Eczema Area and Severity... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
11/15/2023
Locations: Health Concepts, Rapid City, South Dakota
Conditions: Atopic Dermatitis
An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis
Recruiting
Phase 2 study of RPT193 in adults with atopic dermatitis
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
11/14/2023
Locations: Health Concepts, Rapid City, South Dakota
Conditions: Atopic Dermatitis
A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection
Recruiting
The purpose of this study is to learn about the safety and effects of the study medicine called etrasimod for the possible treatment of atopic dermatitis (AD), also called eczema, in adults who have already tried AD treatments taken by mouth or by injection that work all over the body. These adults can have moderate to severe AD. This study is seeking participants who: have AD for at least 1 year have moderate-to-severe AD have tried treatments that work all over the body and saw no effects ar... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
10/25/2023
Locations: Monument Health Rapid City Hospital, Rapid City, South Dakota +2 locations
Conditions: Atopic Dermatitis, Atopic Dermatitis, Unspecified, Eczema, Eczema, Atopic
Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
Recruiting
Multicenter, randomized, double-blind, placebo-controlled, parallel arm clinical study designed to evaluate the efficacy and safety of eblasakimab in participants with moderate-to-severe atopic dermatitis (AD) previously treated with dupilumab.The study consists of a 16-week treatment period and an 8-week follow-up period up to Week 24. Eligible participants will be randomized into one of the 2 treatment arms.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/18/2023
Locations: ASLAN Investigative Site, Rapid City, South Dakota
Conditions: Atopic Dermatitis
Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis
Recruiting
This is a phase 2, multi-center, randomized, placebo-controlled, double-blind, parallel-group, dose-ranging study, conducted in subjects with moderate-to-severe atopic dermatitis.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/04/2022
Locations: AkesoBio Investigative Site 2005, Rapid City, South Dakota
Conditions: Atopic Dermatitis